{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:45:52Z","timestamp":1792017952433,"version":"4.4.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Patients with cancer receiving immune checkpoint inhibitors (CPIs) may experience immune-related adverse events (IRAEs) due to immune system overactivation. Concurrently, infections such as seasonal influenza can be more severe in cancer patients because of their compromised immune function, making influenza vaccination particularly important. In this multicenter retrospective study, we investigated whether influenza vaccination during CPI treatment influences CPI effectiveness and rates of IRAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study across three Swedish centers involving patients with metastatic cancer treated with CPIs\u2014either PD-1\/PD-L1 inhibitors or combination immunotherapy\u2014between January 1, 2016, and December 31, 2021. To address immortal time bias in time-to-event outcomes, different statistical strategies were employed including time-dependent Cox regression and landmark analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In total, 587 patients treated with CPIs during the study period were identified. The most common malignancy was non\u2013small cell lung cancer (NSCLC; 34.4%), followed by cutaneous malignant melanoma (CMM; 32.5%). Time-dependent Cox regression analysis showed that real-world progression-free survival was significantly longer in influenza-vaccinated patients compared with unvaccinated in overall cohort (hazard ratio [HR], 0.59 [95% CI, 0.44 to 0.79]). No statistically significant differences in the occurrence of any grade IRAEs (48.4%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      51.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .455) or multiple IRAEs (15.1%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      19.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .297) between the vaccinated and unvaccinated groups were observed. The survival benefit was more pronounced in patients with CMM, whereas no statistically significant effect was observed in patients with NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Our findings suggest a potential association between influenza vaccination and improved survival in CPI-treated patients, without a corresponding increase in IRAEs, supporting current vaccination recommendations. The observed association in patients with CMM may reflect underlying biological mechanisms and is hypothesis-generating for further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00660","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:59:09Z","timestamp":1770670749000},"page":"1805-1811","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Influenza Vaccination Among Patients With Cancer Treated With Checkpoint Inhibitors: Association With Survival Outcomes and Immune-Related Adverse Events"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-8683","authenticated-orcid":true,"given":"Anthoula","family":"Koliadi","sequence":"first","affiliation":[{"name":"Department of Oncology, Uppsala University Hospital, Uppsala, Sweden"},{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-6200","authenticated-orcid":true,"given":"Evangelos","family":"Digkas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Uppsala University Hospital, Uppsala, Sweden"},{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4014-5391","authenticated-orcid":true,"given":"Ali Inan","family":"El-Naggar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Ullenhag","sequence":"additional","affiliation":[{"name":"Department of Oncology, Uppsala University Hospital, Uppsala, Sweden"},{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-0194","authenticated-orcid":true,"given":"Antonis","family":"Valachis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e2"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101472"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000968"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21203"},{"key":"e_1_3_7_8_2","first-page":"CD015551","article-title":"Vaccines for preventing infections in adults with solid tumours","volume":"4","author":"Hirsch C","year":"2025","unstructured":"Hirsch C, Zorger AM, Baumann M, et al: Vaccines for preventing infections in adults with solid tumours. Cochrane Database Syst Rev 4:CD015551, 2025","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00032"},{"key":"e_1_3_7_10_2","first-page":"CD008983","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman R","year":"2018","unstructured":"Bitterman R, Eliakim-Raz N, Vinograd I, et al: Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2:CD008983, 2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1092"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.07.008"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1474045"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0080"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081195"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102044"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1886725"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.001"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060584"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.10.003"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0353-7"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1904022116"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004022"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:59:55Z","timestamp":1792015195000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1200\/OP-25-00660"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00660","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}